Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

(2015) Lieping Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

KIT in Melanoma: Many Shades of Gray

(2015) Ana Slipicevic et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses

(2015) L. Christiansson et al.   MOLECULAR CANCER THERAPEUTICS

Mast cells as targets for immunotherapy of solid tumors

(2015) Sharon A. Oldford et al.   MOLECULAR IMMUNOLOGY

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Myeloid derived suppressor cells—An overview of combat strategies to increase immunotherapy efficacy

(2015) Oana Draghiciu et al.   OncoImmunology

Targeting KIT on innate immune cells enhances the antitumor activity of checkpoint inhibitors in vivo

(2015) Richard Gedrich et al.   Journal for ImmunoTherapy of Cancer

A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth

(2014) Maria B Lebron et al.   CANCER BIOLOGY & THERAPY

The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: Focus on macrophage polarization of THP-1 cells

(2014) Xian-Feng Wang et al.   CELLULAR IMMUNOLOGY

Imatinib Mesylate Inhibits CD4+CD25+ Regulatory T Cell Activity and Enhances Active Immunotherapy against BCR-ABL- Tumors

(2014) N. Larmonier et al.   JOURNAL OF IMMUNOLOGY

Oxidative Stress Regulates Expression of VEGFR1 in Myeloid Cells: Link to Tumor-Induced Immune Suppression in Renal Cell Carcinoma

(2014) S. Kusmartsev et al.   JOURNAL OF IMMUNOLOGY

Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice

(2014) J.-I. Youn et al.   JOURNAL OF IMMUNOLOGY

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Frequent KIT Mutations in Human Gastrointestinal Stromal Tumors

(2014) Zhi Xu et al.   Scientific Reports

Mast Cells Boost Myeloid-Derived Suppressor Cell Activity and Contribute to the Development of Tumor-Favoring Microenvironment

(2014) L. Danelli et al.   Cancer Immunology Research

Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes

(2014) S. Kitano et al.   Cancer Immunology Research

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab

(2014) Saskia JAM Santegoets et al.   Journal for ImmunoTherapy of Cancer

STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients

(2013) David Vasquez-Dunddel et al.   JOURNAL OF CLINICAL INVESTIGATION

Innate and adaptive immune cells in the tumor microenvironment

(2013) Thomas F Gajewski et al.   NATURE IMMUNOLOGY

Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines

(2013) A Q Butt et al.   ONCOGENE

Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region

(2013) A. V. Reshetnyak et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mast cells impair the development of protective anti-tumor immunity

(2012) Anna Wasiuk et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma

(2012) Farhad Azimi et al.   JOURNAL OF CLINICAL ONCOLOGY

Cutting Edge: Mast Cells Critically Augment Myeloid-Derived Suppressor Cell Activity

(2012) S. J. Saleem et al.   JOURNAL OF IMMUNOLOGY

Cancer classification using the Immunoscore: a worldwide task force

(2012) Jérôme Galon et al.   Journal of Translational Medicine

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Stem Cell Factor Receptor/c-Kit: From Basic Science to Clinical Implications

(2012) Johan Lennartsson et al.   PHYSIOLOGICAL REVIEWS

Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors

(2012) Damien Kee et al.   Therapeutic Advances in Medical Oncology

Targeting Regulatory T Cells in Cancer

(2011) W. L. Byrne et al.   CANCER RESEARCH

Mast Cells in Tumor Microenvironment Promotes the In Vivo Growth of Pancreatic Ductal Adenocarcinoma

(2011) D. Z. Chang et al.   CLINICAL CANCER RESEARCH

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy

(2011) James Finke et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer

(2011) Sahar M.A. Mahmoud et al.   JOURNAL OF CLINICAL ONCOLOGY

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

(2011) Vinod P Balachandran et al.   NATURE MEDICINE

Targeting immune suppressing myeloid-derived suppressor cells in oncology

(2010) Johnny Kao et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Mast cells in allergy and infection: Versatile effector and regulatory cells in innate and adaptive immunity

(2010) Stephen J. Galli et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Mast Cells Mobilize Myeloid-Derived Suppressor Cells and Treg Cells in Tumor Microenvironment via IL-17 Pathway in Murine Hepatocarcinoma Model

(2010) Zhuoshun Yang et al.   PLoS One

The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies

(2009) J. Ozao-Choy et al.   CANCER RESEARCH

Mast Cells as Target in Cancer Therapy

(2009) Tom Kormelink et al.   CURRENT PHARMACEUTICAL DESIGN

SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment

(2008) B. Huang et al.   BLOOD